<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149279</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG9501</org_study_id>
    <secondary_id>C000000121</secondary_id>
    <nct_id>NCT00149279</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer</brief_title>
  <official_title>Randomized Controlled Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer (JCOG9501)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the survival benefit of para-aortic lymphadenectomy in potentially curative
      gastrectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical gastrectomy with regional lymphadenectomy is the only curative treatment option for
      gastric cancer. The extent of lymphadenectomy, however, is controversial. The two European
      randomized trials only reported an increase in operative morbidity and mortality, but failed
      to show survival benefit, in the D2 lymphadenectomy group. We conducted a randomized
      controlled trial to compare the Japanese standard D2 and D2 + para-aortic nodal dissection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1995</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative morbidity and mortality</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of postoperative hospital stay</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
  </secondary_outcome>
  <enrollment>520</enrollment>
  <condition>Gastric Neoplasm</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery: D2 dissection</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery: D2+paraaortic dissection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Preoperatively,

          1. histologically proven adenocarcinoma

          2. 75 years old or younger

          3. forced expiratory volume in one second ≥ 50 %

          4. arterial oxygen pressure in room air ≥ 70 mmHg

          5. creatinine clearance ≥ 50 ml/min

          6. written consent. Intraoperatively

          7. Macroscopic T staging is T2-subserosa, T3, or T4

          8. potentially curative operation is possible

          9. no gross metastasis in para-aortic nodes (frozen section diagnosis not allowed)

         10. peritoneal lavage cytology is negative for cancer cells

        Exclusion Criteria:

          1. Carcinoma in the remnant stomach

          2. Borrmann type 4 (linitis plastica)

          3. synchronous or metachronous malignancy in other organs except for cervical carcinoma
             in situ and colorectal focal cancer in adenoma

          4. past history of myocardial infarction or positive results of exercise ECG

          5. liver cirrhosis, or chronic liver disease with indocyanine green test ≥10%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsuru Sasako, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gastric Surgery Division, National Cancer Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <reference>
    <citation>Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004 Jul 15;22(14):2767-73. Epub 2004 Jun 15.</citation>
    <PMID>15199090</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <keyword>stomach neoplasms</keyword>
  <keyword>lymph node excision</keyword>
  <keyword>abdominal aorta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

